Clinical Features of Patients with Tropheryma Whipplei Detected in Lower Respiratory Tract Samples in China

中国下呼吸道样本中检测到惠氏杆菌的患者的临床特征

阅读:1

Abstract

INTRODUCTION: Tropheryma whipplei (TW) can cause various infections that are relatively rare worldwide. With the development of molecular biology, the ability to detect TW has increased in recent years. However, its significance in lower respiratory tract samples remains unclear. PATIENTS AND METHODS: We collected the clinical data of 5 patients admitted to a tertiary care hospital in Beijing with TW detected by bronchoalveolar lavage fluid (BALF) mNGS and reviewed all case reports of TW-related pneumonia in China (up to November 2024) to analyse the features of this disease among Chinese patients. RESULTS: A total of 41 articles reporting 55 cases were identified. Fifty-two (94.5%) patients had respiratory symptoms. Fifteen (27.3%) patients developed severe pneumonia. Confirmation of TW infection was achieved through methods including the assessment of TW reads and relative abundance (63.6%), empirical treatment (18.2%), lung biopsy histopathology (14.5%), and qPCR confirmation (3.6%). Fifty (90.9%) patients received antibiotic therapy. Fifty-one (92.7%) patients had a good prognosis. CONCLUSION: TW can enter the lower respiratory tract through multiple routes. When TW sequences are detected in lower respiratory tract samples, it is important to consider not only the read and relative abundance but also histopathological findings such as interstitial pneumonia and the presence of PAS- or PASM-positive bacilli within foamy macrophages as they can aid in diagnosing TW infection. MDT discussions and empirical antibiotic therapy targeting TW are viable options when a patient's condition deteriorates. Microbiological testing of saliva, gastric fluid, blood, and faeces may help clarify the source of TW.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。